التفاصيل البيبلوغرافية
| العنوان: |
PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2. |
| المؤلفون: |
Sehn, L. H, Chamuleau, M., Lenz, G., Clausen, M. R., Haioun, C., Izutsu, K., Davies, A., Zhu, J., Oki, T., Szafer‐Glusman, E., Conlon, R., Chiou, H., Ipe, D., Elliot, B., Wu, J., Salles, G. |
| المصدر: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p849-850, 2p |
| مصطلحات موضوعية: |
DIFFUSE large B-cell lymphomas, CLINICAL trials, ANTINEOPLASTIC combined chemotherapy protocols |
| مستخلص: |
Epcoritamab is a subcutaneously administered, bispecific antibody that binds CD3 on T cells and CD20 on B cells, inducing potent and selective T-cell-mediated killing of malignant CD20+ B cells (Hutchings et al., I Lancet i 2021). B Introduction: b In pts with newly diagnosed DLBCL, standard treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has a 5-year progression-free survival (PFS) rate of 67.0%, 58.4%, and 45.8% for International Prognostic Index (IPI) 2, 3, and 4-5, respectively (Ruppert et al., I Blood i 2020). PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R-CHOP VERSUS R-CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): EPCORE DLBCL-2. [Extracted from the article] |
|
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder